Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Monday, September 29, 2014

Low Dose Naltrexone May Improve Multiple Sclerosis Patient Quality of Life

Low Dose Naltrexone for MSLow dose naltrexone (LDN) may be on its way to becoming a new therapeutic agent for multiple sclerosis. Evidence for its efficacy in attenuating multiple sclerosis symptoms is scarce, but results of a phase 3 clinical trial, “A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone,” suggest that LDN enhances the mental health quality of life of patients with multiple sclerosis.
The trial, initiated in 2007 by a group led by Bruce Cree, MD, PhD, at the University of California, San Francisco, sought to evaluate changes in quality of life for multiple sclerosis patients following treatment with 4.5 mg naltrexone (LDN). Eighty patients were enrolled in the trial, and treatment was administered nightly for eight weeks. Of primary interest was a difference in mean score of the multiple sclerosis quality of life inventory (MSQLI54) between LDN-treated and placebo-treated patients.
According to results published in 2010 in the journal Annals of Neurology, at the end of the trial, sixty patients had completed treatment. Ten patients withdrew before the end of the first trial period, but none withdrew due to a multiple sclerosis-LDN adverse event. In fact, one patient withdrew early due to a perceived benefit of treatment. Results from the other ten patients were not available due to database management errors and incomplete quality of life surveys.




~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT and up to date, 
Sign-Up for our email
.

WATCH OUR Multiple Sclerosis recorded
 EDUCATIONAL VIDEOS by Topic: 

.


No comments: